GlobeNewswire PharmaOriginal article
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline
approvedpotravitugPositive
AI Analysis
Summary
Ipsen has completed its acquisition of Memo Therapeutics AG, adding potravitug, a first-in-class anti-BK polyomavirus monoclonal antibody, to its rare disease pipeline.
Outcome Details
Acquisition completed
Importance:7/10
Sentiment:
0.60
M&Arare diseasemonoclonal antibodylate-stage asset
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 22, 2026 5:00 AM